No Data
No Data
Jiangxi Fushine Pharmaceutical's subsidiary will receive a government subsidy of 35.4 million yuan.
Financial Intelligence APP news, Jiangxi Fushine Biotechnology Co., Ltd. ("Fushine Biotech"), a holding subsidiary of Fushine Pharmaceutical (300497.SZ), received a government notice on issuing enterprise development support funds recently, and is expected to receive a subsidy of 35.4 million yuan. The acquisition of the subsidy reflects the recognition and support of the national innovation potential in the field of synthetic biology, and will make the company's funds more abundant. This will further strengthen the company's research and development of new technologies and new processes, promote the innovation of synthetic biology technology, and play an important role in promoting the development of the company's synthetic biology sector.
Jiangxi Fushine Pharmaceutical (300497.SZ): Vice General Manager Liu Ying has completed the shareholding of 36,000 shares.
On June 26th, Gelonhui reported that Jiangxi Fushine Pharmaceutical (300497.SZ) announced that it has recently received a notice from its deputy general manager, Ms. Liu Ying, that the shareholding of the company has been completed. As of the date of the announcement, Ms. Liu Ying has accumulated 36,000 shares of the company through centralized bidding and the amount of shareholding has reached 317,160 yuan. Her shareholding plan has been completed.
Strong Week for Jiangxi Fushine Pharmaceutical (SZSE:300497) Shareholders Doesn't Alleviate Pain of Three-year Loss
Jiangxi Fushine Pharmaceutical (300497.SZ): Completion of Vice President's Shareholding.
Jiangxi Fushine Pharmaceutical (300497.SZ) announced on June 5th that the company disclosed on the Juchao Information website on February 1, 2024 the "Announcement on the Plan of Controlling Shareholders, Actual Controllers, Chairman and Vice Chairman of the Board, and Senior Management to Increase Shareholdings of the Company",Mr. Zhang Xiangming, Vice General Manager of the company, Mr. Wei Haipeng, Vice General Manager, and Ms. Peng Yun, Vice General Manager and Secretary of the Board of Directors, based on their recognition of the company's inherent value and their firm confidence in its future sustainable and healthy development, as well as their wish to protect the interests of shareholders and enhance investor confidence, plan to purchase the company's shares through centralized bidding or within six months of the above-mentioned announcement in accordance with applicable legal regulations.
Jiangxi Fushine Pharmaceutical (300497.SZ) partially completed shareholding of 104,900 shares by senior executives.
Jiangxi Fushine Pharmaceutical (300497.SZ) announced that Zhang Xiangming, Vice President; Wei Haipeng, Vice President; and Vice President...
Fuxiang Pharmaceutical (300497.SZ): Signed the “Termination Agreement on Shareholders' Special Rights”
Gelonghui, May 30丨Fuxiang Pharmaceutical (300497.SZ) announced that currently, since Ling Kai Pharmaceutical is planning an initial public offering and listing plan on the Hong Kong Stock Exchange Limited, in order to comply with the regulations and requirements of laws and regulations, the Hong Kong Stock Exchange, the Hong Kong Securities and Futures Commission, the China Securities Regulatory Commission, etc., the parties agreed to terminate the performance compensation, repurchase rights, and shareholder special “Shareholders' Agreement” on the day before the date Ling Kai Pharmaceutical first submitted the listing application form to the Hong Kong Stock Exchange Before signing the “Termination of Rights Agreement”
No Data